Ignite Creation Date:
2025-12-18 @ 4:14 AM
Ignite Modification Date:
2025-12-18 @ 4:14 AM
Study NCT ID:
NCT00763009
Status:
None
Last Update Posted:
2018-04-13 00:00:00
First Post:
2008-09-24 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Persantine: Variation in Response Trial
Sponsor:
None
Organization:
Study Overview
Official Title:
Persantine: Variation in Response Trial
Status:
None
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Limited numbers of patients qualified for trial
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Participants will receive three doses of Persantine intravenously for the research study. Before and after receiving the Persantine doses, patients will have an echocardiogram and coronary artery blood flow will be measured. Blood tests,measure the function of the adenosine transporter. In addition variations in the gene for the adenosine transporter will be evaluated.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: